Skip to main content
SpringerLink
Log in

Adjuvant and Neoadjuvant Therapy of NSCLC

  • Chapter
  • First Online:
Lung Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 2247 Accesses

Abstract

For patients with operable non-small cell lung cancer (NSCLC), surgery has long been the standard of care. However, despite complete resection, 5-year survival rates have been disappointing with about 50% of patients eventually suffering relapse and death from disease. Efforts at improving survival for patients with operable NSCLC have examined the addition of chemotherapy and/or radiation in the preoperative (neoadjuvant or induction) and postoperative (adjuvant) settings.

Thoracic radiation when given after surgery has led to a reduction in local recurrence but has not improved overall survival. A postoperative radiotherapy (PORT) meta-analysis published in 1998 raised significant concerns about the potential hazards of PORT. More recent retrospective studies of PORT have found it safe and not associated with excessive deaths from intercurrent disease. Postoperative radiation is not recommended for completely resected stage I and II NSCLC patients, and its use should be individualized in patients with stage III disease. PORT is currently recommended only for patients at high risk of local relapse (extensive nodal involvement or positive surgical margin).

Early trials of postoperative chemotherapy failed to demonstrate a consistent benefit. These trials suffered from poor design with heterogeneous patient populations, inadequate trial size, and less active drug regimens. A meta-analysis examining the role of chemotherapy in NSCLC published in 1995 found a trend in favor of adjuvant cisplatin-based chemotherapy. These findings led to renewed interest in adjuvant chemotherapy for NSCLC, and larger trials with more active chemotherapy regimens were undertaken. Several of these trials have demonstrated a clear survival advantage for patients treated with cisplatin-based adjuvant therapy. Updated meta-analyses have confirmed the benefit of postoperative chemotherapy in NSCLC. Postoperative cisplatin-based chemotherapy is now the standard of care for completely resected stage II and III NSCLC patients with good performance status.

Preoperative or induction chemotherapy trials were investigated prior to the positive adjuvant clinical trial data. Support for this concept came from improved survival seen in the locally advanced but inoperable NSCLC patients where chemotherapy administered prior to definitive chest radiation therapy had improved survival. Possible advantages of preoperative administration of chemotherapy include radiographic and pathologic tumor response assessment, earliest treatment of clinically undetectable micrometastatic disease, and improved compliance. Randomized trials in stage IIIA patients found a significant survival benefit but were small studies and their findings remain controversial. Randomized trials in earlier stages have supported the use of chemotherapy in operable NSCLC, but overall survival differences have not achieved statistical significance. Meta-analyses have found significant benefit for preoperative chemotherapy in operable NSCLC. At this time, stronger data exist in support of adjuvant chemotherapy in patients with operable NSCLC. Preoperative chemotherapy should only be administered in the clinical trial setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710-1717

    Article  PubMed  CAS  Google Scholar 

  2. The Lung Cancer Study Group (1986) Effects of postoperative mediastinal radiation on completely resected stage II and stage III squamous cell carcinoma of the lung. N Engl J Med 315:1377-1381

    Article  Google Scholar 

  3. PORT Meta-analysis Trialists Group (1988) Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 352:257-263

    Google Scholar 

  4. Munro AJ (1998) What now for postoperative radiotherapy for lung cancer? Lancet 352(9124):250-251

    Article  PubMed  CAS  Google Scholar 

  5. Machtay M, Lee JH, Shrager JB et al (2001) Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small cell lung carcinoma. J Clin Oncol 19:3912-3917

    PubMed  CAS  Google Scholar 

  6. Lally BE, Zelterman D, Colasanto JM, Haffty GB, Detterbeck FC, Wilson LD (2006) Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results Database. J Clin Oncol 24(19):2998-3006

    Article  PubMed  Google Scholar 

  7. Douillard J, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 7:719-727

    Article  PubMed  CAS  Google Scholar 

  8. Okawara G, Ung YC, Markman BR et al (2004) Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 44:1-11

    Article  PubMed  Google Scholar 

  9. Pisters KMW, Evans WK, Azzoli CG et al (2007) Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small cell lung cancer guidelines. J Clin Oncol 25:5506-5518

    Article  PubMed  Google Scholar 

  10. Pisters KMW, Lechevalier T (2005) Adjuvant chemotherapy in completely resected non-small cell lung cancer. J Clin Oncol 23:3270-3278

    Article  PubMed  CAS  Google Scholar 

  11. Holmes EC, Gail M (1986) Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 4:710-715

    PubMed  CAS  Google Scholar 

  12. Niiranen A, Niitamo-Korhonen S, Kouri M, Assendelft A, Mattson K, Pyrhönen S (1992) Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 10(12):1927-1932

    PubMed  CAS  Google Scholar 

  13. Feld R, Rubinstein L, Thomas PA, The Lung Cancer Study Group (1993) Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. J Natl Cancer Inst 85(4):299-306

    Article  PubMed  CAS  Google Scholar 

  14. Non-small cell lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909

    Article  Google Scholar 

  15. Scagliotti GV, Fossati R, Torri V et al (2003) Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Natl Cancer Inst 95:1453-1461

    Article  PubMed  CAS  Google Scholar 

  16. The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350:351-360

    Article  Google Scholar 

  17. Le Chevalier T, Arriagada R, Bergman B et al (2008) Long-term results of the international adjuvant lung cancer trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). J Clin Oncol 26:398s Abstr 7507

    Google Scholar 

  18. Waller D, Peake MD, Stephens RJ et al on behalf of all BLT Participants (2004) Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26:173-182

    Article  PubMed  CAS  Google Scholar 

  19. Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 353:2589-2597

    Article  Google Scholar 

  20. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Watson DM et al (2006) Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. [Abstract]. J Clin Oncol 24(Suppl 18):A7007

    Google Scholar 

  21. Strauss GM, Herndon JE, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Group. J Clin Oncol 26:5043-5051

    Article  PubMed  CAS  Google Scholar 

  22. Stewart LA, Burdett S, Tierney JF, Pignon J, on behalf of The NSCLC Collaborative Group (2007) Surgery and adjuvant chemotherapy compared to surgery alone in non-small cell lung cancer: a meta-analysis using individual patient data from randomized clinical trials. J Clin Oncol ASCO Annual meeting proceedings part I. 25(18S, June 20 Suppl):A7552

    Google Scholar 

  23. Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol 26:3552-3559

    Article  PubMed  Google Scholar 

  24. Piedbois P, Byuse M (2004) Meta-analyses based on abstracted data: A step in the right direction, but only a first step. J Clin Oncol 22:3839-3840

    Article  PubMed  Google Scholar 

  25. Bria E, Gralla R, Raftopoulos H et al (2005) Does adjuvant chemotherapy improve survival in non small cell lung (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit. J Clin Oncol 23(Suppl 16S):abstr7140

    Google Scholar 

  26. Sedrakyan A, van Der Meulen J, O’Byrne K et al (2004) Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 128(3):414-419

    Article  PubMed  Google Scholar 

  27. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M (2004) Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22(19):3860-3867

    Article  PubMed  CAS  Google Scholar 

  28. Kato H, Ichinose Y, Ohta M et al (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721

    Article  PubMed  CAS  Google Scholar 

  29. HHamada C, Ohta M, Wada H et al (2004) Survival benefit of oral UFT of adjuvant chemotherapy after completely resected non-small cell lung cancer [Abstract]. J Clin Oncol 22(14 Supp):A70

    Google Scholar 

  30. Kikuchi T, Carbone DP (2007) Proteomics analysis in lung cancer: challenges and opportunities. Respirology 12(1):22-28

    Article  PubMed  Google Scholar 

  31. Dziadziuszko R, Hirsch F (2008) Advances in genomic and proteomic studies of non-small cell lung cancer: clinical and translational research perspective. Clin Lung Cancer 9(2):78-84

    Article  PubMed  Google Scholar 

  32. Kosaka R, Yatabe Y, Onozato R et al (2009) Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treat lung adenocarcinoma. J Thorac Oncol 4:22-29

    Article  PubMed  Google Scholar 

  33. D’Amico TA, Brooks KR, Moore Joshi MB et al (2006) Serum protein expression predicts recurrence in patients with early stage lung cancer after resection. Ann Thorac Surg 81:1982-1987

    Article  PubMed  Google Scholar 

  34. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS (2006) K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 8(1):30-38

    Article  PubMed  CAS  Google Scholar 

  35. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983-991

    Article  PubMed  CAS  Google Scholar 

  36. Filipits M, Pirker R, Dunant A et al (2007) Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 25(19):2735-2740

    Article  PubMed  CAS  Google Scholar 

  37. Potti A, Mukherjee S, Petersen R et al (2006) A genomic strategy to refine prognosis in early stage non-small cell lung cancer. N Engl J Med 355:570-580

    Article  PubMed  CAS  Google Scholar 

  38. Martini N, Kris M, Flehinger B et al (1993) Preoperative chemotherapy for stage IIIa(N2) lung cancer: The Memorial Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55:1365-1374

    Article  PubMed  CAS  Google Scholar 

  39. Burkes R, Shepherd R, Blackstein M et al (2005) Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3N2) unresectable non-small cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 47:103-109

    Article  PubMed  Google Scholar 

  40. Darwish S, Minotti V, Crino L et al (1994) Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer. Am J Clin Oncol 17:64-67

    Article  PubMed  CAS  Google Scholar 

  41. Vokes E, Bitran J, Hoffman P et al (1989) Neoadjuvant vindesine, etoposide and cisplatin for locally advanced non-small cell lung cancer. Chest 96:110-113

    Article  PubMed  CAS  Google Scholar 

  42. Elias A, Skarin A, Leong T et al (1997) Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 17:147-161

    Article  PubMed  CAS  Google Scholar 

  43. Pisters K, Kris M, Gralla R et al (1993) Pathologic complete response in advanced non-small cell lung cancer following preoperative chemotherapy: Implications for the design of future non-small cell lung cancer combined modality trials. J Clin Oncol 11:1757-1762

    PubMed  CAS  Google Scholar 

  44. Patel J, Blum M, Argiris A (2004) Induction chemotherapy for resectable non-small cell lung cancer. Oncology 18:1591-1602

    PubMed  Google Scholar 

  45. Pisters K, Ginsberg R, Giroux D et al (2000) Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. J Thorac Cardiovasc Surg 119:429-439

    Article  PubMed  CAS  Google Scholar 

  46. Albain K, Rusch V, Crowley J et al (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA (N2) and IIIB NSCLC: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1892

    PubMed  CAS  Google Scholar 

  47. Faber LP, Kettle F, Warren WH et al (1989) Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 47:266-272

    Article  Google Scholar 

  48. Strauss G, Herndon J, Sherman D et al (1992) Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell lung carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 10:1237-1244

    PubMed  CAS  Google Scholar 

  49. Betticher D, Hsu Schmitz S, Roth A et al (2005) Neoadjuvant therapy with docetaxel and cisplatin in patients with non-small cell lung cancer, stage IIIA, pN2: A large phase II study with 59 months of follow-up. Lung Cancer 49:S14

    Article  Google Scholar 

  50. Betticher D, Hsu Schmitz S, Totsch M et al (2003) Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol 21:1752-1759

    Article  PubMed  CAS  Google Scholar 

  51. Van Zandwijk N, Smit E, Kramer G et al (2000) Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 18:2658-2664

    PubMed  Google Scholar 

  52. Migliorino M, De Marinis F, Nelli F et al (2002) A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for stage III non-small cell lung cancer. Lung Cancer 35:319-327

    Article  PubMed  Google Scholar 

  53. Choi I, Oh D, Kwon J et al (2005) Paclitaxel/platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. Jpn J Clin Oncol 35:6-12

    Article  PubMed  Google Scholar 

  54. Garrido P, Rosell R, Torres A et al (2005) Docetaxel, cisplatin and gemcitabine as neoadjuvant treatment in stage IIIAN2 and T4N0-1 non-small cell lung cancer patients. Final results of SLCG phase II trial 9901. Lung Cancer 49:S14

    Article  Google Scholar 

  55. Esteban E, Fernancez Y, Vieitez J et al (2005) Cisplatin plus gemcitabine with or without vinorelbine as neoadjuvant therapy for radically treatable stage III non-small cell lung cancer. Preliminary results of a randomized study of the GON. Lung Cancer 49:S40

    Article  Google Scholar 

  56. Lorent N, De Leyn P, Lievens Y et al (2004) Long term survival of surgically staged IIIA-N2 non-small cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 15:1645-1653

    Article  PubMed  CAS  Google Scholar 

  57. Cappuzzo F, De Marinis F, Nelli F et al (2003) Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally advanced non-small cell lung cancer. Lung Cancer 42:355-361

    Article  PubMed  Google Scholar 

  58. De Marinis F, Nelli F, Migliorino M et al (2003) Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA(N2) non-small cell carcinoma. Cancer 98:1707-1715

    Article  PubMed  Google Scholar 

  59. Brechot J, Saintigny P, Azorin J et al (2005) A phase II randomized study of gemcitabine-cisplatin versus mitomycin-ifosfamide-cisplatin as neoadjuvant chemotherapy in resectable stage IIIA non-small cell lung cancer. Lung Cancer 49:S175

    Google Scholar 

  60. Marks R, Streitz J, Deschamps C et al (2001) Response rate and toxicity of preoperative paclitaxel and carboplatin in patients with resectable non-small cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 20:abstr1355

    Google Scholar 

  61. Tsuboi M, Ohira T, Hayashi A et al (2005) Preoperative induction chemotherapy with weekly paclitaxel and carboplatin for clinical-stage IB-IIIA non-small cell lung cancer. Lung Cancer 49:S175

    Article  Google Scholar 

  62. Kunitoh H, Hato H, Tsuboi M, et al. (2005) A randomized phase II trial of preoperative docetaxel and cisplatin or docetaxel alone in clinical stage IB/II non-small cell lung cancer: Initial resort of Japan Clinical Oncology Group Trial. J Clin Oncol 23(16S):abstr 7119

    Google Scholar 

  63. Abratt R, Lee J, Han J et al (2005) Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. Lung Cancer 49:S92

    Google Scholar 

  64. Lothaire P, Berghmans Th, Lafitte J et al (2003) Resectability after two different chemotherapy regimens: results of the first step of a phase II randomized trial in initially resectable stage I-IIIA non-small cell lung cancer conducted by the European Lung Cancer Working Party. Lung Cancer 41(Suppl 2):S63

    Article  Google Scholar 

  65. Socinski M, Detterbeck F, Gralla R et al (2005) Induction chemotherapy with gemcitabine-containing regimens in stage I-II non-small cell lung cancer: Initial results of the GINEST Project. Lung Cancer 49:S40

    Article  Google Scholar 

  66. Sommers E, Ramnath N, Robinson L et al (2005) Neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. Lung Cancer 49:S96-S97

    Article  Google Scholar 

  67. Roth J, Fossella F, Komaki R et al (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86:673-680

    Article  PubMed  CAS  Google Scholar 

  68. Roth J, Atkinson E, Fossella F et al (1998) Long-term followup of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 21:1-6

    Article  PubMed  CAS  Google Scholar 

  69. Rosell R, Gomez-Codina J, Camps C et al (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153-158

    Article  PubMed  CAS  Google Scholar 

  70. Rosell R, Gomez-Codina J, Camps C et al (1999) Preresectional chemotherapy in stage IIIA non-small cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 47:7-14

    Article  Google Scholar 

  71. Bradbury P, Shepherd FA (2007) Chemotherapy and surgery for operable NSCLC. Lancet 369:1903-1904

    Article  PubMed  Google Scholar 

  72. Pass H, Pogrebniak H, Steinberg S et al (1992) Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis. Ann Thorac Surg 53:992-998

    Article  PubMed  CAS  Google Scholar 

  73. Zhou Q, Liu L, Li L et al (2003) A randomized clinical trial of preoperative neoadjuvant chemotherapy followed by surgery in the treatment of stage III non-small cell lung cancer. Lung Cancer 41(Suppl 2):S45-S46

    Article  Google Scholar 

  74. Nagai K, Tsuchiya R, Mori T et al (2003) A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 125:254-260

    Article  PubMed  Google Scholar 

  75. Depierre A, Milleron B, Moro-Sibilot D et al (2001) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIA non-small cell lung cancer. J Clin Oncol 20:247-253

    Article  Google Scholar 

  76. Depierre A, Westeel V, Milleron B et al (2003) 5 year results of the French Randomized study comparing preoperative chemotherapy followed by surgery and primary surgery in resectable stage I (except T1N0), II and IIIA non-small cell lung cancer. Lung Cancer 41(Suppl 2):S62

    Article  Google Scholar 

  77. Sorensen J, Riska H, Ravn J et al (2005) Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3. J Clin Oncol 23(16S):abstr7146

    Google Scholar 

  78. Pisters KM, Vallieres E, Bunn PA et al (2007) S9900: surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow-up on a phase III trial. J Clin Oncol 25(18S):abstr 7520

    Google Scholar 

  79. Gilligan D, Nicolson M, Smith I et al (2007) Preoperative chemotherapy in patients with respectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review. Lancet 369:1929-1937

    Article  PubMed  CAS  Google Scholar 

  80. Scagliotti GV, Pastorino U, Vansteenkiste JF et al (2008) A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S.T. J Clin Oncol 26(Suppl):abstr 7508

    Google Scholar 

  81. Canela M, Maestre J, Rodriguez-Paniagua M et al (2005) NATCH Trial update. Lung Cancer 49:S93

    Article  Google Scholar 

  82. Berghmans T, Paesmans M, Meert A et al (2005) Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer 49:3-23

    Article  Google Scholar 

  83. Burdett S, Stewart L, Rydzewska L et al (2006) A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 1:611-621

    Article  PubMed  Google Scholar 

  84. Pignon JP, Burdett S (2005) Letter to the editor. Lung Cancer 51:261-262

    Article  Google Scholar 

  85. Siegenthaler M, Pisters K, Merriman K et al (2001) Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 71:1105-1112

    Article  PubMed  CAS  Google Scholar 

  86. Martin J, Ginsberg R, Abolhoda A et al (2001) Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy. Ann Thorac Surg 72:1149-1154

    Article  PubMed  CAS  Google Scholar 

  87. Perrot E, Guibert B, Mulsant P et al (2005) Preoperative chemotherapy does not increase complications after non-small cell lung cancer resection. Ann Thorac Surg 80:423-427

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 301402, Houston, TX, 77230-1402, USA

    Katherine Pisters

Authors
  1. Katherine Pisters
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine Pisters .

Editor information

Editors and Affiliations

  1. M. D. Anderson Cancer Center, University of Texas, Holcombe Blvd. 1515, Houston, 77030, U.S.A.

    David J. Stewart

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pisters, K. (2010). Adjuvant and Neoadjuvant Therapy of NSCLC. In: Stewart, D. (eds) Lung Cancer. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-524-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-524-8_6

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-523-1

  • Online ISBN: 978-1-60761-524-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation